Krystal Biotech, Inc. Stock price

Equities

KRYS

US5011471027

Biotechnology & Medical Research

Market Closed - Nasdaq 04:15:00 2024-03-28 pm EDT 5-day change 1st Jan Change
177.9 USD +0.41% Intraday chart for Krystal Biotech, Inc. +4.79% +43.42%
Sales 2024 * 255M Sales 2025 * 416M Capitalization 5.01B
Net income 2024 * 47M Net income 2025 * 141M EV / Sales 2024 * 17.6 x
Net cash position 2024 * 535M Net cash position 2025 * 689M EV / Sales 2025 * 10.4 x
P/E ratio 2024 *
102 x
P/E ratio 2025 *
35.9 x
Employees 229
Yield 2024 *
-
Yield 2025 *
-
Free-Float 86.99%
More Fundamentals * Assessed data
Dynamic Chart
1 day+0.41%
1 week+4.79%
Current month+11.58%
1 month+9.11%
3 months+39.27%
6 months+50.92%
Current year+43.42%
More quotes
1 week
166.11
Extreme 166.11
180.24
1 month
159.29
Extreme 159.29
189.97
Current year
107.50
Extreme 107.5
189.97
1 year
77.10
Extreme 77.095
189.97
3 years
38.86
Extreme 38.8563
189.97
5 years
22.02
Extreme 22.02
189.97
10 years
8.03
Extreme 8.03
189.97
More quotes
Managers TitleAgeSince
Chief Executive Officer 59 16-04-14
Founder 59 16-04-14
Chief Tech/Sci/R&D Officer - 22-06-30
Members of the board TitleAgeSince
Director/Board Member 58 16-10-31
Founder 59 16-04-14
Director/Board Member 69 17-05-31
More insiders
Date Price Change Volume
24-03-28 177.9 +0.41% 392,925
24-03-27 177.2 +1.74% 349,198
24-03-26 174.2 +2.78% 259,456
24-03-25 169.5 +1.30% 268,136
24-03-22 167.3 -1.48% 207,402

Delayed Quote Nasdaq, March 28, 2024 at 04:15 pm EDT

More quotes
Krystal Biotech, Inc. is an integrated, commercial-stage biotechnology company. It is focused on the discovery, development, and commercialization of genetic medicines to treat diseases with high unmet medical needs. Its product candidates in various stages of clinical and preclinical development include VYJUVEK, KB407, KB408, KB707, KB105, KB104, KB104, and KB301. Its commercial product VYJUVEK is a non-invasive, topical, redo sable gene therapy designed to deliver two copies of theCOL7A1 gene when applied directly to DEB wounds. VYJUVEK is designed to treat DEB at the molecular level by providing the patient’s skin cells the template to make normal COL7 protein, thereby addressing the fundamental disease-causing mechanism. KB407 is developed for the treatment of Cystic Fibrosis. KB408 is developed for the treatment of Alpha-1 Antitrypsin Deficiency. KB707 is developed for the treatment of solid tumors. KB105 is developed for TGM1-Deficient Autosomal Recessive Congenital Ichthyosis.
Related indices
More about the company
Trading Rating
Investor Rating
ESG Refinitiv
C
More Ratings
Sell
Consensus
Buy
Mean consensus
BUY
Number of Analysts
11
Last Close Price
177.9 USD
Average target price
185.9 USD
Spread / Average Target
+4.48%
Consensus
  1. Stock
  2. Equities
  3. Stock Krystal Biotech, Inc. - Nasdaq